Skip to main content
. 2009 Apr 22;157(4):581–596. doi: 10.1111/j.1476-5381.2008.00084.x

Table 3.

The effects of the potassium channel blockers 4-AP (KV) and charybdotoxin (BKCa) alone and in the presence of the VOCC blockers nifedipine or mibefradil or the chloride channel blocker niflumic acid on the concentration–response curve to U46619 in endothelium-intact rings

pEC50 Rmax % n
Control 7.58 ± 0.07 107.5 ± 4 5
+4-AP 8.26 ± 0.47 123 ± 2.6 5#
+4-AP + Nifedipine 7.35 ± 0.07 98.6 ± 3.3 5
+4-AP + Mibefradil 8.33 ± 0.04 126 ± 2 5#
Control 7.41 ± 0.08 107.7 ± 5 5
+4-AP + NFA 7.45 ± 0.1 102 ± 6 5
+4-AP + DIDS 7.53 ± 0.04 104.5 ± 2.3 4
+4-AP + 2-APB 8.26 ± 0.05 120.2 ± 5 5#
Control 7.68 ± 0.05 104.9 ± 3 6
+Charybdotoxin 8.37 ± 0.06 142 ± 3.6 6#
+Charybdotoxin + Nifedipine 8.33 ± 0.05 145 ± 3 5#
+Charybdotoxin + Mibefradil 7.74 ± 0.05 105 ± 3 6
+Charybdotoxin + NFA 7.44 ± 0.09 109.6 ± 6 5
+Charybdotoxin + DIDS 7.56 ± 0.03 102 ± 2 6

4-AP, 4-aminopyridine; 2-APB, 2-amino ethoxy diphenylborate; DIDS, 4,4′-diisothiocyanostilbene-2,2′-disulphonic acid; NFA, niflumic acid; U46619, 9,11-dideoxy-9α, 11α-methanoepoxy prostaglandin F; VOCC, voltage-operated calcium channel.

#Significantly different from control (P < 0.001).